Cargando…

Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program

Early antiretroviral therapy (ART) initiation is a recommended public health approach for the prevention of HIV-1 transmission. In this cohort study, we included 13132 serodiscordant couples. ART was initiated for patients with CD4+ T cell counts less than 200 cells/uL, 350 cells/uL, and 500 cells/u...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Pengtao, Tang, Zhenzhu, Lan, Guanghua, Zhu, Qiuying, Chen, Huanhuan, You, Yinghui, Yang, Xiaoyi, Liang, Shujia, Chen, Yi, Xing, Hui, Liao, Lingjie, Feng, Yi, Shen, Zhiyong, Ruan, Yuhua, Shao, Yiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821824/
https://www.ncbi.nlm.nih.gov/pubmed/29467460
http://dx.doi.org/10.1038/s41598-018-21791-2
_version_ 1783301566686560256
author Liu, Pengtao
Tang, Zhenzhu
Lan, Guanghua
Zhu, Qiuying
Chen, Huanhuan
You, Yinghui
Yang, Xiaoyi
Liang, Shujia
Chen, Yi
Xing, Hui
Liao, Lingjie
Feng, Yi
Shen, Zhiyong
Ruan, Yuhua
Shao, Yiming
author_facet Liu, Pengtao
Tang, Zhenzhu
Lan, Guanghua
Zhu, Qiuying
Chen, Huanhuan
You, Yinghui
Yang, Xiaoyi
Liang, Shujia
Chen, Yi
Xing, Hui
Liao, Lingjie
Feng, Yi
Shen, Zhiyong
Ruan, Yuhua
Shao, Yiming
author_sort Liu, Pengtao
collection PubMed
description Early antiretroviral therapy (ART) initiation is a recommended public health approach for the prevention of HIV-1 transmission. In this cohort study, we included 13132 serodiscordant couples. ART was initiated for patients with CD4+ T cell counts less than 200 cells/uL, 350 cells/uL, and 500 cells/uL respectively. This divided the ART treated couples into three groups. Univariate and multivariate intention-to-treat analyses were performed to examine the association between the study groups. Early-ART initiation was associated with a 45% lower risk of partner infection than was late-ART initiation (AHR 0.55, 95% CI, 0.37–0.81). Mid-ART initiation was associated with a 39% lower risk of partner infection than was late-ART initiation (AHR 0.61, 95% CI, 0.48–0.78). However, the risk reduction between the early and mid-ART groups was not significant. Drug compliance (AHR 1.55, 95% CI 1.03–2.35) and increased baseline viral load (AHR 1.41, 95% CI 1.33–1.51) were associated with an increased risk of infections among partners in the treatment. Prevention of HIV transmission as a result of early ART initiation was feasible on national and regional scales; however, many factors, such as the motivation to commence ART, adherence, and attrition, may affect the impact of this strategy in programmatic settings.
format Online
Article
Text
id pubmed-5821824
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-58218242018-02-26 Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program Liu, Pengtao Tang, Zhenzhu Lan, Guanghua Zhu, Qiuying Chen, Huanhuan You, Yinghui Yang, Xiaoyi Liang, Shujia Chen, Yi Xing, Hui Liao, Lingjie Feng, Yi Shen, Zhiyong Ruan, Yuhua Shao, Yiming Sci Rep Article Early antiretroviral therapy (ART) initiation is a recommended public health approach for the prevention of HIV-1 transmission. In this cohort study, we included 13132 serodiscordant couples. ART was initiated for patients with CD4+ T cell counts less than 200 cells/uL, 350 cells/uL, and 500 cells/uL respectively. This divided the ART treated couples into three groups. Univariate and multivariate intention-to-treat analyses were performed to examine the association between the study groups. Early-ART initiation was associated with a 45% lower risk of partner infection than was late-ART initiation (AHR 0.55, 95% CI, 0.37–0.81). Mid-ART initiation was associated with a 39% lower risk of partner infection than was late-ART initiation (AHR 0.61, 95% CI, 0.48–0.78). However, the risk reduction between the early and mid-ART groups was not significant. Drug compliance (AHR 1.55, 95% CI 1.03–2.35) and increased baseline viral load (AHR 1.41, 95% CI 1.33–1.51) were associated with an increased risk of infections among partners in the treatment. Prevention of HIV transmission as a result of early ART initiation was feasible on national and regional scales; however, many factors, such as the motivation to commence ART, adherence, and attrition, may affect the impact of this strategy in programmatic settings. Nature Publishing Group UK 2018-02-21 /pmc/articles/PMC5821824/ /pubmed/29467460 http://dx.doi.org/10.1038/s41598-018-21791-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Liu, Pengtao
Tang, Zhenzhu
Lan, Guanghua
Zhu, Qiuying
Chen, Huanhuan
You, Yinghui
Yang, Xiaoyi
Liang, Shujia
Chen, Yi
Xing, Hui
Liao, Lingjie
Feng, Yi
Shen, Zhiyong
Ruan, Yuhua
Shao, Yiming
Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program
title Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program
title_full Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program
title_fullStr Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program
title_full_unstemmed Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program
title_short Early antiretroviral therapy on reducing HIV transmission in China: strengths, weaknesses and next focus of the program
title_sort early antiretroviral therapy on reducing hiv transmission in china: strengths, weaknesses and next focus of the program
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5821824/
https://www.ncbi.nlm.nih.gov/pubmed/29467460
http://dx.doi.org/10.1038/s41598-018-21791-2
work_keys_str_mv AT liupengtao earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT tangzhenzhu earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT languanghua earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT zhuqiuying earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT chenhuanhuan earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT youyinghui earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT yangxiaoyi earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT liangshujia earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT chenyi earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT xinghui earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT liaolingjie earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT fengyi earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT shenzhiyong earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT ruanyuhua earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram
AT shaoyiming earlyantiretroviraltherapyonreducinghivtransmissioninchinastrengthsweaknessesandnextfocusoftheprogram